Aurigene reports results of AUR101 in phase-II study in patients with moderate-to-severe psoriasis EP News Bureau Dec 19, 2022 The Indus-III study met its primary endpoint of PASI-75 response at 12 weeks at the 400 mg BID dose, when compared to placebo
